Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Of course, no one really knows. There's been talk about $.05, $.10, $.25, and even a dollar, but I've got this one set aside for a little bit longer term and higher gains than most. I'm looking for something between $2.25 and $2.75.
True, but if they sell tomorrow it could mean a three day weekend! lol
Last shake of the day. Few takers, lol.
If you concede that you don't know what's going on, how can you turn right around and say something sounds (smells) pretty fishy? Which is it? Do you think you know what's going on or don't you?
RNVA will be the Crown Jewel of the OTC, 2018.
MM's are forced to shake shares loose. Haha.
Every so often there's a lag between markedly substantial news and the resulting share price. When I've seen it, it plays out longer and stronger, though it's a bit of an anomaly. I'm hoping this is one of those situations. This was truly a milestone for Pharmacyte and illustrates the company's momentum and overall motivation to succeed.
Normally, I wouldn't speculate on how the day is going to go, but based on the 15 and 30 min charts, I share your enthusiasm.
Well, I haven't voted yet, so if I get the call I'll likely get an elongated response. Should be interesting.
Hmm. Did they state who they were representing?
MM's are just doing what they do. They give and take, and if you know the drill you can enter and exit on other people's dime. They've got their jobs down, and as long as they stay within reasonable tolerances, no flags are thrown and they can profit. When the time comes, they'll switch gears and flow with the market.
Don't count your cells until they're encapsulated.
Market Watch April 02, 2018
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R) , announced that vials of cells from PharmaCyte's Master Cell Bank (MCB) have been shipped by Eurofins Lancaster Laboratories (Eurofins) to Austrianova's encapsulation facility in Thailand. The cells from the MCB will be encapsulated and then tested by Austrianova after encapsulation. This post-encapsulation testing will generate the remaining data required by the U.S. Food and Drug Administration (FDA) to be included in PharmaCyte's Investigational New Drug Application (IND). For the cells to be shipped and accepted into Austrianova's GMP encapsulation facility, they had to pass mandatory sterility and mycoplasma testing by Eurofins. PharmaCyte's Chief Executive Officer, Kenneth L. Waggoner, stated, "We are extremely pleased to make this announcement. It represents a major step forward in preparations for our planned clinical trial to treat locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). After encapsulation, further testing will be done by Austrianova. The data from these tests, along with data from the tests done by Eurofins and its subcontractors, will be included as an integral part of our IND." Austrianova's Chief Executive Officer, Brian Salmons, said, "We are excited to receive vials of cells from the MCB produced by Eurofins. The next step will be the encapsulation of these cells followed by another round of sterility testing and numerous quality control tests. After this is completed, the encapsulated cells in a syringe will be shipped to PharmaCyte for use in its planned clinical trial." Before the cells were shipped, they had undergone and passed numerous tests completed by Eurofins and its subcontractors. Several tests are still ongoing. The large number of tests that PharmaCyte must complete on the cells are necessary to meet the FDA's requirements. The lengthy amount of time it has taken to complete these tests is because PharmaCyte is using genetically modified live human cells as part of its combination product that utilizes the Cell-in-a-Box(R) technology plus low dose ifosfamide as a novel therapy to treat LAPC. About PharmaCyte Biotech PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box(R) ." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte's therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient's tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a "bio-artificial liver" and activate the chemotherapy drug at the site of the cancer. This "targeted chemotherapy" has proven effective and safe to use in past clinical trials and results in no treatment related side effects. PharmaCyte's therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box(R) technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a "bio-artificial pancreas" for purposes of insulin production. Safe Harbor This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission. More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte's Investor Relations Department. View source version on businesswire.com: https://www.businesswire.com/news/home/20180402005386/en/ CONTACT: Investor Relations: PharmaCyte Biotech, Inc. Dr. Gerald W. Crabtree Investor Relations Department 917.595.2856 Email: Info@PharmaCyte.com SOURCE: PharmaCyte Biotech, Inc. Copyright Business Wire 2018 (END) Dow Jones Newswires April 02, 2018 09:00 ET (13:00 GMT) Story ID: 20180402SN005981 Keywords: COMPANY NEWS, THIRD-PARTY CONTENT, PRESS RELEASES AUTO-PUBLISHED ON TICKER, DOW JONES CONTENT SET SN, PRESS RELEASE WIRES, PRESS RELEASES ON NEWSWIRES, CHEMICALS-ALL, GRAND CENTRAL ASSET CLASS EQUITIES, BUSINESS WIRE, BASIC MATERIALS, SIGNIFICANT STORY Symbols: PMCB
Excellent News! Cells Shipped, CHECK! Go PMCB!
I'd like to see you stay out of your shell for awhile. This board can only benefit from reasonable feedback such as yours.
"Critical Payments...ancient." Get up to date.
False Statement Alert: RNVA is not in "default." It no longer amazes me what some people will say.
Regarding Spinoff: It's a bonus, not your paycheck. No one is basing their RNVA investment on the potential for spinoff shares, and if they are, that's their strategy and good luck to them. Whether or not the spinoff comes to fruition or how it may ultimately be structured is purely speculative at this point. Like I said, it's bonus material, not grounds for investment. Everyone knows that. So if you're upset about spinoff timeline and whatnot, you're not seeing the forest through the trees. RNVA is making marked progress in instituting its business plan, and that's why people are investing in it.
Haha. Maybe you should try video games or lottery tickets. You get your results within minutes.
Seamus confirmed that the spinoff is intended within the next six months.
I would agree with you up to about three weeks ago, or, when myself and many saavy traders made an entry into RNVA.
I know better than to believe that four consecutive down days of this magnitude constitute "sinking." You're responding to a very experienced trader. My post wasn't an invitation to hammer at the downside possibility, which you have a strong record of doing. Rather, it was an inquiry to this board to rationalize what appears to be a not-so-serious request to R/S.
I'm surprised RNVA didn't better establish or 'sell' its motivation for recommending yes votes in this proxy. Without any detailed and compelling explanation of that recommendation, no one in their right mind would vote yes. I'm baffled by this. If I was at the helm and recommending yes votes, I would certainly state my case for each, especially since the logical uninformed outcome would be 'no'. Did I miss something?
I should clarify that any spinoff shares will provide a new date of shareholder of record, one which you would most likely fall within.
Well, for purposes of spinoff, no, because there hasn't been an announcement regarding spinoff details as far as I know. I have been away for several days however.
There was some language at some point that suggested blank votes would be considered 'yes' votes, as I recall.
Mine did, yes.
We have until eod 04/17 to vote.
Affirmative. If you didn't get the proxy link and a control number, you're not a shareholder of record as of 3/12.
Checking in while on vacation...Go RNVA!
By R/S you must mean you did no DD.
CDEL's making up.
Just curious, but have you established some kind of basis for comparison?
It's funny that y'all were being accused of pumping this stock, yet you're all still here after the dump. I still fully expect to do very well on this one. I'm thinking it could be my best play this whole year.
I believe we're just about to find out which way she breaks. LOL, I love the suspense. Holding strong.
I don't know, nor can I guess because that's the same as saying I don't know and I've already said that, lol. It would be nice to form a hammer on the daily. But it would be nice to close green also, though I don't believe we will. Tomorrow, I believe we will, but I certainly don't know that either. Honestly, as much as I want the price to go up, I've got a great deal of patience because I'm seeing the forest through the trees on this play, which isn't even something I would normally look for on this exchange. That's my last free post for the day, but I've got places to be anyway. Good luck, Ragnar. And tell Lagertha I said hey.
I suspect it had everything to do with two things: 1, This stock has been in a freefall for a very long time, so there weren't any devoted longs holding, and 2, it ramped from .004 to .02 in just a few short days. That's plenty of reason to take your winnings and walk when many might consider reason number 1. That's all I have. It's irrational.
It's not the run that has no credit, it was the drop. Completely baseless.
I'm looking at a strong group of traders right here. Everyone else has vanished. Cheers!
That was amazeballs. When those pre-market trades of just a few hundred bucks printed, you had to know people set their sells in the .006's. MM's ate that right up. Wow! I could feel the fear radiating from my monitor. That's always exhilarating. People just don't know how to pull it together. Of course, I had the comfort of being green all the way to the bottom of that mess, lol. I think I'll go run some errands.